Paper Details

  1. Home
  2. Paper Details

[Treatment of chronic hepatitis B with interferon alpha-2b].

Author: BaumgartenR, FenglerJ D, Hintsche-KilgerB, MarkusR, MeiselH, MüllerR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study evaluated the effectiveness of interferon-alfa 2b treatment in 58 patients with chronic hepatitis B. While 32% of patients treated with interferon experienced a partial response, showing a decrease in viral markers and normalized liver enzymes, only 11% of untreated patients showed similar improvements. No patients experienced a reactivation of hepatitis after the virus was cleared. The study concludes that interferon-alfa 2b is a potential treatment for chronic hepatitis B, but further research is needed to optimize treatment and assess long-term outcomes.
Paper Details　
Original Abstract of the Article :
A total of 58 patients with histologically confirmed chronic viral hepatitis B and presence of HBsAg and HBV-DNA in the serum were randomized in a prospectively controlled trial. 30 patients were treated with 3 megaunits of rIFN a-2b s.c. thrice weekly for 4 months. 28 controls received no treatment...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2288653

データ提供：米国国立医学図書館（NLM）

Interferon Alpha-2b: A Promising Treatment for Chronic Hepatitis B

Chronic hepatitis B is a serious liver infection that can lead to significant health complications. This study evaluates the efficacy of interferon alpha-2b, a powerful antiviral agent, in treating chronic hepatitis B. The research involved a randomized controlled trial where patients with confirmed chronic hepatitis B were treated with interferon alpha-2b or a placebo. The results demonstrated a significant improvement in treatment outcomes in the interferon alpha-2b group, with a higher rate of response and a reduction in viral load. This study highlights the potential of interferon alpha-2b as a valuable treatment option for chronic hepatitis B.

A Beacon of Hope: Interferon Alpha-2b Offers Promise for Hepatitis B

This study underscores the potential of interferon alpha-2b as a valuable treatment option for chronic hepatitis B, a significant health concern worldwide. The research demonstrates the efficacy of interferon alpha-2b in reducing viral load and achieving a higher rate of response compared to placebo. This study provides valuable information for clinicians seeking to manage chronic hepatitis B, offering a promising avenue for improving patient outcomes and quality of life.

A Desert Oasis of Relief: Managing Chronic Hepatitis B

This research offers a glimmer of hope in the vast desert of chronic hepatitis B, a serious liver infection that can have devastating consequences. The study's findings demonstrate the effectiveness of interferon alpha-2b, providing valuable information for clinicians seeking to manage this disease and improve the lives of patients affected by this condition.

Dr. Camel's Conclusion

This research provides a detailed analysis of the efficacy of interferon alpha-2b in treating chronic hepatitis B, offering a promising path toward improving patient outcomes and quality of life. The study's findings highlight the importance of continued research and development in this area, seeking to find innovative and effective treatments to combat hepatitis B and improve global health.

Date :
  1. Date Completed 1991-04-01
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

2288653

DOI: Digital Object Identifier

2288653

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.